Open Access

MicroRNA-7: a promising new target in cancer therapy

  • Juanjuan Zhao1,
  • Yijing Tao1,
  • Ya Zhou2,
  • Nalin Qin1,
  • Chao Chen1,
  • Dan Tian1 and
  • Lin Xu1Email author
Cancer Cell International201515:103

https://doi.org/10.1186/s12935-015-0259-0

Received: 22 September 2015

Accepted: 20 October 2015

Published: 29 October 2015

Abstract

The incidence of tumors with life-threatening effects has increased gradually over time; however, the mechanisms involved in tumor development have not been fully elucidated. Recent studies have shown that microRNA-7 (miR-7), which is endogenous non-coding RNA molecules of approximately 23 nucleotides, plays an important role in the occurrence and development of tumors as a key tumor suppressor. Mechanistic evidence showed that miR-7 is closely related to the growth, metastasis, and prognosis of various malignant tumors through regulating different target molecules, which suggest that miR-7 may be a new target for the clinical diagnosis and treatment of various tumors. In this review, we summarize current knowledge of the relationship between miR-7 and tumor development, diagnosis, and treatment.

Keywords

Tumors MiR-7 Diagnosis Treatment

Background

MicroRNAs (miRNAs) are small noncoding RNAs that posttranscriptionally regulating target gene expression through base pairing to partially complementary sites to prevent protein accumulation by repressing translation or by inducing mRNA degradation [1, 2]. The primary transcripts of miRNA (pri-miRNA) are cleaved into precursor miRNA (pre-miRNA) by nuclear RNase III Drosha, and further processed to mature miRNAs by cytoplasmic RNase III Dicer [3, 4]. Up to data, the involvement of miRNAs in human cancer has led to extensive research [57]. More and more evidences showed that miRNAs were not only dysregulated in almost all types of cancers but also were potential specific signatures for the characterization of poorly differentiated tumors, which might harbor relevant clinical implications. Further studies suggested that miRNAs in cancers could be divided into two types including oncogenic miRNAs (Oncomirs) and tumor suppressor miRNAs. Oncomirs are reported upregulated in cancer cells and contributed to carcinogenesis by inhibiting tumor suppressor genes. Conversely, tumor suppressor miRNAs are documented could prevent cancer development by inhibiting the expression of oncogenes. Experimental data in some animal tumor models showed that silencing oncomirs with miRNA inhibitors or replacing tumor suppressor miRNAs with synthetic miRNA mimics may be valuable strategy for the treatment of solid and hematological malignancies, which suggesting a particularly promising in translational therapy against tumors.

MicroRNA-7 (miR-7) was first identified by Lagos-Quintana in 2001 [8]. In humans, miR-7 is encoded by three different genomic loci 9q21, 15q26, 19q13 respectively. The products of three different DNA sequences (termed as pri-miR-7-1, pri-miR-7-2, and pri-miR-7-3) can be processed into the same mature miR-7 sequence which comprising 23 nucleotides [9]. The mature miR-7 is then incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA (Fig. 1). Many studies have reported that miR-7 is enriched in a variety of normal tissues and involved in both the development of multiple organs and biological functions of cells [10, 11]. Moreover, some tissues related factors could regulate the expression of miR-7; for example, transcription factor NeuroD/Beta2 can bind to the promoter region of miR-7 and successively regulate its expression [12]. And Human antigen R (HuR) could mediate the binding of Musashi homolog 2 (MSI2) to the conserved terminal loop of pri-miR-7, then modify miR-7 processing in normal cells [13]. Recent evidence showed that miR-7 plays an important role in growth, migration, and invasion of multiple cancers [1417]; hence, it may be a new promising target for cancer therapies.
Fig. 1

Structure of the human miR-7 hairpin precursors and mature sequences. MiR-7 is transcribed from three different genomic loci on chromosomes 9, 15, 19 into primary miR-7 transcripts (pri-miR-7-1, pre-miR-7-2, pri-miR-7-3 respectively), which are processed into hairpin precursor molecules (pre-miR-7-1, pre-miR-7-2, pre-miR-7-3), and then further into the same mature miR-7 sequences, which are incorporated into the RISC complex and guided to miR-7 target mRNAs to repress their expression

MiR-7 and breast cancer

E-cadherin and Vimentin were reported played crucial roles in epithelial-mesenchymal transition (EMT) process, including monolayer scattering, independent growth, migration, and invasion, of breast cancer cells, which closely related to metastasis of cancer cells [18]. A study of breast cancer tissue specimens revealed a positive correlation between the expression levels of miR-7 and E-cadherin, and a negative correlation between the expression levels of miR-7 and Vimentin [19], indicating miR-7 might be involved in the metastasis of breast cancer. Importantly, the expression level of miR-7 in metastatic breast cancer tissues was significantly lower than that in normal breast tissues. Furthermore, an increase in the expression level of miR-7 could dramatically inhibit the growth and invasiveness of breast cancer cells in animal models, indicating that miR-7 plays an important role in metastasis of breast cancer [19].

Successive studies have demonstrated that miR-7 can negatively regulate a variety of molecules involved in breast cancer cell growth, metastasis, and invasion. P21-activated kinase 1 (PAK1) is expressed at high levels in many human cancer tissues and is closely related to mitosis of tumor cells, regeneration of the cytoskeleton structure, cell migration and apoptosis [20]. Reddy et al. showed that miR-7 binds to a complementary site in the 3′ untranslated region (UTR) of the PAK1 mRNA to inhibit its expression and downregulate the kinase activity of the protein, resulting in the inhibition of breast cancer growth [21]. In addition, Webster et al. reported that miR-7 inhibits epidermal growth factor receptor (EGFR) expression and the protein kinase B signal transmission pathway, thereby regulating the growth and metastasis of breast cancer cells [22]. MiR-7 can also inhibit the invasion and metastasis of breast cancer cells by negatively regulating focal adhesion kinase (FAK), an important signaling factor that controls cell proliferation and locomotor activity [19]. In line with these data, the expression level of FAK is increased in metastatic tumors with poor prognosis [23]. In additions, miR-7 also can inhibit brain metastasis of breast cancer and the self-renewal capacity of breast cancer stem-like cells by regulating the expression of Krüppel-like factor4 (KLF4) [24].

The underlying mechanism through which miR-7 regulates breast cancer cell growth and metastasis is complex, it dose not involve only the above mentioned molecular targets and signal transmission pathways but also some transcription factors and DNA damage repair processes. For example, Li et al. demonstrated that miR-7 can reactivate the Ras association domain family 1A (Raf1A) and tumor suppressors claudin-6 by targeting the gene encoding homeobox B3 (HoxB3), therefore inhibit the growth and colony formation capacity of breast cancer cells [25]. In addition, Yu et al. showed that miR-7 binds to the 3′UTR of the mRNA encoding SET domain-containing (lysine methyltransferase) 8 (SET8) to downregulate its expression in breast cancer cells [26]. In higher eukaryotes, SET8 is involved in gene transcription and the cell cycle progression of breast cancer cells, and is also related to a variety of biological processes, including DNA damage and repair [27]. Moreover, MiR-7 can reduce the monomethylation of histone H4 lysine 20 by targeting SET8, then inhibiting the occurrence, development, and invasion of breast cancer [26]. In addition, some studies reported that miR-7 accelerates spontaneous DNA damage and sensitizes breast cancer cells to this type of damage. Taken together, these findings indicate that miR-7 can regulate the development and progression of breast cancer through multiple targets or pathways; hence, miR-7 based breast cancer gene therapy is expected to become an important area of related research.

The current understanding of the mechanism of regulating miR-7 expression in breast cancer cells still is limited. MiR-7 expression is upregulated by the transcription factor HoxD10. When the level of HoxD10 is decreased, the expression level of miR-7 is also decreased. Successively, the expression level of its target molecule PAK1 is increased significantly, the growth and invasiveness of breast cancer cells is enhanced [21]. Due to the complexity of the mechanisms of regulation of miRNAs, additional analyses on off factors that affect miR-7 expression in breast cancer are required.

MiR-7 and lung cancer

MiR-7 plays an important role in suppressing the migration, colony formation, and cell-cycle progression of lung cancer cells. Reducing the amount of miR-7 can promote the growth and metastasis of human lung carcinoma A549 and H1299 cells significantly [28]. Furthermore, increasing the level of miR-7 can reduce the levels of cell-cycle-associated proteins and inhibit the proliferation of human lung cancer cells, suggesting that miR-7 is closely related to development of lung cancer. It is well known that epidermal growth factor receptor (EGFR) is critical factor for the growth and metastasis of human lung cancer cells [29, 30]. Mechanistic evidence showed that miR-7 can inhibit the proliferation of lung cancer cells through regulating the expression of EGFR by binding to the 3′UTR region of EGFR mRNA [28]. In addition, Xiong et al. showed that miR-7 downregulated the expression of the gene encoding BCL-2, thereby inhibiting the proliferation and promoting the apoptosis of lung adenocarcinoma A549 cells [31]. Other studies also reported that miR-7 targets and downregulates proteasome activator 28 subunit γ, which contributes to the carcinogenesis of non-small cell lung cancer, and inhibits apoptosis and accelerates the cell cycle in lung cancer cells [32]. Moreover, Zhou et al. showed that the regulatory effect of miR-7 on the growth of human lung cancer cells may be associated with the downregulated expression of Solute Carrier Family 7 (Amino Acid Transporter Light Chain, L System), Member 5 (SLC7A5), which was a member of the l-type amino acid transporter (LAT) family and was involved in the growth of cancer cells [3335]. In contrast to these literatures, other studies showed that inhibition of miR-7 could reduce the growth of lung cancer cell line A549 cells [36]. Based on these contradictory data, we propose that this might reflect the fact that miR-7 plays a crucial role in lung cancer cell growth, invasion, and metastasis, although the mechanisms involved in regulating these processes may be complex, which was closely related to the cellular context, growth conditions and specific targeted genes.

A number of studies have shown that miR-7 also is involved in the signal transduction and regulatory processes of other membrane-bound proteins in lung cancer cells, such as the pattern-recognition molecules Toll-like receptor 9 (TLR9). Our recent study showed that miR-7 may negatively regulate the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway by acting on PI3Kregulatory subunit 3, thereby blocking the TLR9 signal transduction process and inhibiting cancer cell growth and metastasis [37]. Furthermore, activation of TLR9 signaling can inhibit the cleavage of the endogenous miR-7 precursor in lung cancer cells by inducing the expression of human antigen R (HuR), therefore reduce the level of mature miR-7 and accelerate the growth and metastatic progression of the cells [38].

The treatment of lung cancer could lead to an acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). However, in about 50 % of patients with TKIs resistance, this resistance is caused by a T790M mutation in exon 20 of the EGFR gene [39]. Interestingly, Rai et al. showed that expression of exogenous miR-7 in nude mice bearing RPC-9 and H1975 lung cancer cells, which have a high tolerance to TKIs, inhibited the growth of tumors, suggesting that miR-7, as a tumor suppressor miRNA, may be an important target for lung cancer gene therapy [40].

MiR-7 and brain cancer

MiR-7 is enriched in the brain and regulates neuronal differentiation, maturation, and survival [41].There is increasing evidence that miR-7 is a robust suppressor of the growth, metastasis, and invasion of glioblastoma; for example, Liu et al. showed that miR-7 can suppress glioblastomagenesis by regulating the PI3K/AKT and Raf/mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) pathways, which are downstream signaling pathways of the EGFR [42]. Furthermore, miR-7 may regulate brain tumorigenesis by targeting oncogenic proteins and critical factors such as c-KIT, Y box binding protein 1, AKT2, cell division control protein 42, cyclin-dependent kinase 6, and transforming growth factor β2 (TGF-β2), which can also affect the expression of miR-7 in a feedback loop [43]. Similar to the anti-angiogenic drug sunitinib, miR-7 can reduce vascularization in the chick chorioallantoic membrane assay. Furthermore, local application of miR-7 to neuroblastoma model mice harboring human glioblastoma xenografts reduces angiogenesis and tumor cell proliferation by targeting the 3′UTR of the FAK mRNA [44]. In addition, miR-7 also can inhibit glioblastoma cell invasion by downregulating the expression levels of p-ERK1/2, p-AKT, Raf-1, and cyclin D1 [42]. There also are some reports suggesting that brain-enriched ciRS-7, a circular RNA containing 70 conserved miR-7 target sites, can downregulate the expression of miR-7 and promote the development of neuroblastomas and astrocytomas [45]. Conversely, miR-671 can release the expression of miR-7 by binding to ciRS-7 [46]. Overall, these findings suggest that miR-7 may be a potential therapeutic target to suppress brain tumorigenesis, metastasis, and invasion.

MiR-7 and other tumors

Recently, a large number of studies have demonstrated that miR-7 is related to liver cancer [47], colorectal cancer [48], gastric tumor [49], and ovarian cancer [50]. Using immunohistochemistry, real-time PCR, and luciferase reporter genes assay, Needhamsen et al. showed that the human gene encoding paired box 6 (PAX6) is an putative target of miR-7 [51]. PAX6 is a highly conserved transcription factor that is expressed in colorectal cancer cells and plays an important regulatory role in the development of colorectal cancer [52]. Overexpression of PAX6 in human colonic adenocarcinoma SW480 cells activates the ERK/PI3K signaling pathway and upregulates the expression levels of MMP2 and MMP9, resulting in the enhancement of cancer cell growth, proliferation, and metastatic capacity. By contrast, miR-7 reduces PAX6 expression in colorectal cancer cell lines and inhibits the corresponding signaling through the ERK/PI3K pathway, resulting in downregulated growth, proliferation, and metastasis of these cells significantly [53]. Meanwhile, in vivo experiments revealed that miR-7 could bind to the 3′ UTR of the mRNA encoding Yin Yang 1, which was a multifunctional transcription factor and was reported contributed to growth of cancer cells, and inhibit its expression, thereby attenuated colorectal cancer cell growth and invasion [54].

Fang et al. showed that miR-7 arrests hepatocellular carcinoma cells in the G0/G1 phase and negatively regulates the PI3K/AKT pathway by targeting AKT, mammalian target of rapamycin, and ribosomal protein S6 kinase, which are key signaling molecules involved in the promotion of liver cancer cell growth and metastasis [55]. MiR-7 may also play an important role in discriminating between benign and malignant cells in B-chronic lymphocytic leukemia [56]. In addition, Zhao et al. showed that miR-7 binds to the 3′ UTR of the mRNA encoding insulin-like growth factor 1 receptor and induces cadherin expression and reversal of the epithelial-mesenchymal transition of gastric cancer cells, successively inhibited gastric cancer metastasis [57]. A number of other types of cancer are also reported closely related to miR-7 (summarized in Table 1), suggesting that this miRNA may be a novel clinical target for the treatment of a variety of tumors.
Table 1

The targets of miR-7 in different tumor types

Tumor type

Target site(s)

Reference(s)

Role of target site

Breast cancer

FAK, PAK1, EGFR, KLF4, HoxB3, SET8

[19, 21, 22, 2426]

Suppressor

Lung cancer

PA28γ, BCL-2, EGFR, SLC7A5, HuR

[32, 35, 38 39]

Suppressor

Hepatocellular carcinoma

CCNE1, PI3KCD, mTOR, p70S6 K, GSK-3B

[48, 54]

Suppressor

Glioma

EGFR, C-KIT, FAK, ERK, ciRS-7

[4244, 46]

Suppressor

Colorectal cancer

XRCC2, PAX6, YY1

[49, 52, 53]

Suppressor

Gastric cancer

EGFR, IGF1R

[42, 56]

Suppressor

Acute myelocytic leukemia

TET2

[58]

Suppressor

Urothelium carcinoma

FGFR3

[59]

Suppressor

Cervical cancer

XIAP

[60]

Suppressor

Renal carcinoma

None reported

[61]

Oncogene

Melanoma

IRS-2

[62]

Suppressor

Ovarian cancer

EGFR, ERK

[50]

Suppressor

Oral cancer

RECK

[63]

Oncogene

Neuroblastoma

4-HPR, EGCG

[64]

Suppressor

Pancreatic carcinoma

MAPK

[65]

suppressor

Pleural mesothelioma

None reported

[66]

Suppressor

Schwannoma tumors

EGFR, ACK1, PAK1

[67]

Suppressor

Tongue squamous carcinoma

IGF1R

[68]

Suppressor

FAK focal adhesion kinase, PAK1 p21 activated kinase 1, EGFR epidermal growth factor receptor, KLF4 Krüppel like factor 4, HoxB3 homeobox B3, SET8 SET domain-containing (lysine methyltransferase) 8, PA28γ proteasome activator 28 subunit γ, HuR human antigen R, PI3KCD phosphoinositide 3-kinase catalytic subunit delta, mTOR mammalian target of rapamycin, p70S6 K ribosomal protein S6 kinase, GSK- glycogen synthase kinase 3, ciRS-7 circular RNA sponge for miR-7, XRCC2 X-ray repair complementing defective repair in Chinese hamster cells 2, PAX6 paired box 6, YY1 Yin Yang 1, IGF1R insulin-like growth factor 1 receptor, TET2 tet methylcytosine dioxygenase 2, FGFR3 fibroblast growth factor receptor 3, XIAP X-linked inhibitor of apoptosis protein, IRS-2 insulin receptor substrate 2, RECK reversion-inducing cysteine-rich protein with Kazal motifs, 4-HPR N-(4-hydroxyphenyl) retinamide, EGCG (-)-epigallocatechin-3-gallate, MAPK mitogen-activated protein kinase, ACK1 associated cdc42 kinase 1

MiR-7 and tumor diagnosis, therapy

Multiple studies have suggested that miR-7 can be used as a potential diagnostic marker of cancer. For example, the expression level of miR-7 is significantly lower in lung cancer tissues than normal lung tissues, and downregulation of miR-7 expression is associated with lung cancer metastasis [32]. Kitano et al. showed that miR-7 expression level predicts thyroid cancer prognosis with an accuracy of approximately 76 % [69]. Other groups used non-invasive detection methods and found that the serum level of miR-7 is significantly lower in patients with colorectal cancer than healthy controls [70]. Moreover, fecal expression levels of miR-7 was remarkable difference between colorectal cancer patients and healthy controls, suggesting that non-invasive detection of miR-7 can be used for the auxiliary diagnosis of colorectal cancer [71]. In addition, other studies have suggested that miR-7 may be an important clinical predictor of recurrence. For example, Duncavage et al. showed that the expression level of miR-7 in relapsed lung cancer patients is significantly lower than that in healthy individuals, suggesting a relationship between reduced expression of miR-7 and lung cancer recurrence [72].

To the therapy against cancer, the related progression still is limited but promising. Overexpression of miR-7 using a eukaryotic expression vector can inhibit the growth of TKI-resistant lung cancer cell significantly in vivo. Tazawa et al. constructed an oncolytic adenovirus that upregulated miR-7 expression and induced apoptosis of human tumor cells through the activation of the transcription factor E2F1/miR-7/EGFR pathway, suggesting a potential new method of inducing tumor cell death by controlling miR-7 levels [73]. In addition, Lee et al. reported that overexpression of miR-7 increases the radiosensitivity of cancer cells, suggesting that this miRNA may have a positive effect on radiation therapy of tumors [74]; however, further analyses are required to clarify the relationship between tumor diagnosis/treatment and the expression levels of miR-7 in different tissues and organs. In all, the development of miR-7-based therapeutic strategy, including the application of efficient synthetic systems for miR-7 delivery, remains to be fully investigated in future.

Conclusion

In this review, we have tried to discuss miR-7 as a promising target in cancers. Although substantial progress has been made in the mechanisms by which miR-7 controls tumor cell growth, proliferation, invasion, and metastasis, however, a number of issues require further investigation, such as the precise regulatory mechanisms of miR-7, the relationships between its target genes, and the ways in which targeting miR-7 can be used to develop agents that have desirable effects on distinct type of cancers, which will provide robust and valuable information related to the clinical diagnosis, treatment, and prognoses of various cancers.

Declarations

Authors’ contributions

All of authors carried out reading the related literatures and drafting the manuscript. Xu designed the outline of manuscript. All authors read and approved the final manuscript.

Acknowledgements

This review manuscript was supported by Program for New Century Excellent Talents in University, Ministry of Education of China (NCET-12-0661), National Natural Science foundation of China (31370918, 81260398), International Cooperation Foundation of Guizhou Province (2010-7031), Specific Foundation for the Scientific Educational Talent of President of Guizhou Province (09C457), Project of Guizhou Provincial Department of Science and Technology (2009C491) and Zunyi Medical College Start-up Fund (2008F-329).

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Immunology, Zunyi Medical College
(2)
Department of Medical Physics, Zunyi Medical College

References

  1. Li X, Yang W, Lou L, Chen Y, Wu S, Ding G. microRNA: a promising diagnostic biomarker and therapeutic target for hepatocellular carcinoma. Dig Dis Sci. 2014;59(6):1099–107.View ArticlePubMedGoogle Scholar
  2. Pichler M, Calin GA. MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients. Br J Cancer. 2015;113(4):569–73.View ArticlePubMedGoogle Scholar
  3. Burger K, Gullerova M. Swiss army knives: non-canonical functions of nuclear Drosha and Dicer. Nat Rev Mol Cell Biol. 2015;16(7):417–30.View ArticlePubMedGoogle Scholar
  4. Akahane T. Clinicopathological and prognostic significance of the microRNA processing enzyme DICER1 mRNA expression in colorectal cancer patients. Mol Clin Oncol. 2013;1(2):267–73.PubMed CentralPubMedGoogle Scholar
  5. Ren F, Ding H, Huang S, Wang H, Wu M, Luo D, Dang Y, Yang L, et al. Expression and clinicopathological significance of miR-193a-3p and its potential target astrocyte elevated gene-1 in non-small lung cancer tissues. Cancer Cell Int. 2015;15:80.PubMed CentralView ArticlePubMedGoogle Scholar
  6. Katoh M. Cardio-miRNAs and onco-miRNAs: circulating miRNA-based diagnostics for non-cancerous and cancerous diseases. Front Cell Dev Biol. 2014;2:61.PubMed CentralView ArticlePubMedGoogle Scholar
  7. Tao Y, Li Y, Zheng W, Zhao J, Guo M, Ya Zhou, et al. Antisense oligonucleotides against microRNA-21 reduced the proliferation and migration of human colon carcinoma cells. Cancer Cell Int. 2015;15:77.PubMed CentralView ArticlePubMedGoogle Scholar
  8. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science. 2001;294(5543):853–8.View ArticlePubMedGoogle Scholar
  9. Kalinowski FC, Brown RA, Ganda C, Giles KM, Epis MR, Horsham J, et al. microRNA-7: a tumor suppressor miRNA with therapeutic potential. Int J Biochem Cell Biol. 2014;54:312–7.View ArticlePubMedGoogle Scholar
  10. Yan B, Wang ZH, Zhu CD, Guo JT, Zhao JL. MicroRNA repertoire for functional genome research in tilapia identified by deep sequencing. Mol Biol Rep. 2014;41(8):4953–63.View ArticlePubMedGoogle Scholar
  11. Kredo-Russo S, Mandelbaum AD, Ness A, Alon I, Lennox KA, Behlke MA, et al. Pancreas-enriched miRNA refines endocrine cell differentiation. Development. 2012;139(16):3021–31.View ArticlePubMedGoogle Scholar
  12. Kredo-Russo S, Ness A, Mandelbaum AD, Walker MD, Hornstein E. Regulation of pancreatic microRNA-7 expression. Exp Diabetes Res. 2012;2012:695214.PubMed CentralView ArticlePubMedGoogle Scholar
  13. Choudhury NR, de Lima Alves F, de Andrés-Aguayo L, Graf T, Cáceres JF, Rappsilber J, et al. Tissue-specific control of brain-enriched miR-7 biogenesis. Genes Dev. 2013;27(1):24–38.PubMed CentralView ArticlePubMedGoogle Scholar
  14. Marzioni M, Agostinelli L, Candelaresi C, Saccomanno S, De Minicis S, Maroni L, et al. Activation of the developmental pathway neurogenin-3/microRNA-7a regulates cholangiocyte proliferation in response to injury. Hepatology. 2014;60(4):1324–35.View ArticlePubMedGoogle Scholar
  15. Ma J, Fang B, Zeng F, Pang H, Zhang J, Shi Y, et al. Curcumin inhibits cell growth and invasion through up-regulation of miR-7 in pancreatic cancer cells. Toxicol Lett. 2014;231(1):82–91.View ArticlePubMedGoogle Scholar
  16. Meza-Sosa KF, Pérez-García EI, Camacho-Concha N, López-Gutiérrez O, Pedraza-Alva G, Pérez-Martínez L. MiR-7 promotes epithelial cell transformation by targeting the tumor suppressor KLF4. PLoS One. 2014;9(9):e103987.PubMed CentralView ArticlePubMedGoogle Scholar
  17. Liu Z, Liu Y, Li L, Xu Z, Bi B, Wang Y, et al. MiR-7-5p is frequently downregulated in glioblastoma microvasculature and inhibits vascular endothelial cell proliferation by targeting RAF1. Tumour Biol. 2014;35(10):10177–84.View ArticlePubMedGoogle Scholar
  18. Díaz-López A, Moreno-Bueno G, Cano A. Role of microRNA in epithelial to mesenchymal transition and metastasis and clinical perspectives. Cancer Manag Res. 2014;6:205–16.PubMed CentralPubMedGoogle Scholar
  19. Kong X, Li G, Yuan Y, He Y, Wu X, Zhang W, et al. MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression. PLoS One. 2012;7(8):e41523.PubMed CentralView ArticlePubMedGoogle Scholar
  20. Radu M, Semenova G, Kosoff R, Chernoff J. PAK signalling during the development and progression of cancer. Nat Rev Cancer. 2014;14(1):13–25.PubMed CentralView ArticlePubMedGoogle Scholar
  21. Reddy SD, Ohshiro K, Rayala SK, Kumar R. MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res. 2008;68(20):8195–200.PubMed CentralView ArticlePubMedGoogle Scholar
  22. Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem. 2009;284(9):5731–41.View ArticlePubMedGoogle Scholar
  23. Jia J, Martin TA, Ye L, Jiang WG. FAP-α (Fibroblast activation protein-α) is involved in the control of human breast cancer cell line growth and motility via the FAK pathway. BMC Cell Biol. 2014;15:16.PubMed CentralView ArticlePubMedGoogle Scholar
  24. Okuda H, Xing F, Pandey PR, Sharma S, Watabe M, Pai SK, et al. miR-7 suppresses brain metastasis of breast cancer stem-like cells by modulating KLF4. Cancer Res. 2013;73(4):1434–44.PubMed CentralView ArticlePubMedGoogle Scholar
  25. Li Q, Zhu F, Chen P. miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer. Biochem Biophys Res Commun. 2012;424(1):28–33.View ArticlePubMedGoogle Scholar
  26. Yu N, Huangyang P, Yang X, Han X, Yan R, Jia H, et al. microRNA-7 suppresses the invasive potential of breast cancer cells and sensitizes cells to DNA damages by targeting histone methyltransferase SET8. J Biol Chem. 2013;288(27):19633–42.PubMed CentralView ArticlePubMedGoogle Scholar
  27. Dulev S, Tkach J, Lin S, Batada NN. SET8 methyltransferase activity during the DNA double-strand break response is required for recruitment of 53BP1. EMBO Rep. 2014;15(11):1163–74.View ArticlePubMedGoogle Scholar
  28. Chan LW, Wang FF, Cho WC. Genomic sequence analysis of EGFR regulation by microRNAs in lung cancer. Curr Top Med Chem. 2012;12(8):920–6.View ArticlePubMedGoogle Scholar
  29. Li J, Zheng Y, Sun G, Xiong S. Restoration of miR-7 expression suppresses the growth of Lewis lung cancer cells by modulating epidermal growth factor receptor signaling. Oncol Rep. 2014;32(6):2511–6.PubMedGoogle Scholar
  30. Blumenberg M. Differential transcriptional effects of EGFR inhibitors. PLoS One. 2014;9(9):e102466.PubMed CentralView ArticlePubMedGoogle Scholar
  31. Xiong S, Zheng Y, Jiang P, Liu R, Liu X, Chu Y. MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. Int J Biol Sci. 2011;7(6):805–14.PubMed CentralView ArticlePubMedGoogle Scholar
  32. Xiong S, Zheng Y, Jiang P, Liu R, Liu X, Qian J, et al. Proteasome activator PA28 gamma regulates p53 by enhancing its MDM2-mediated degradation. EMBO J. 2008;27(6):852–64.View ArticleGoogle Scholar
  33. Dann SG, Ryskin M, Barsotti AM, Golas J, Shi C, Miranda M, et al. Reciprocal regulation of amino acid import and epigenetic state through Lat1 and EZH2. EMBO J. 2015;34(13):1773–85.View ArticlePubMedGoogle Scholar
  34. Lindskog C, Edlund K, Mattsson JS, Micke P. Immunohistochemistry-based prognostic biomarkers in NSCLC: novel findings on the road to clinical use? Expert Rev Mol Diagn. 2015;15(4):471–90.View ArticlePubMedGoogle Scholar
  35. Zhou C, Chen H, Han L, Wang A, Chen LA. Identification of featured biomarkers in different types of lung cancer with DNA microarray. Mol Biol Rep. 2014;41(10):6357–63.View ArticlePubMedGoogle Scholar
  36. Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005;33(4):1290–7.PubMed CentralView ArticlePubMedGoogle Scholar
  37. Xu L, Wen Z, Zhou Y, Liu Z, Li Q, Fei G, et al. MicroRNA-7-regulated TLR9 signaling-enhanced growth and metastatic potential of human lung cancer cells by altering the phosphoinositide-3-kinase, regulatory subunit 3/Akt pathway. Mol Biol Cell. 2013;24(1):42–55.PubMed CentralView ArticlePubMedGoogle Scholar
  38. Li YJ, Wang CH, Zhou Y, Liao ZY, Zhu SF, Hu Y, et al. TLR9 signaling repressed tumor suppressor miR-7 expression through up-regulation of HuR in human lung cancer cells. Cancer Cell Int. 2013;13(1):90.PubMed CentralView ArticlePubMedGoogle Scholar
  39. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer. 2009;10(4):281–9.PubMed CentralView ArticlePubMedGoogle Scholar
  40. Rai K, Takigawa N, Ito S, Kashihara H, Ichihara E, Yasuda T, et al. Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol Cancer Ther. 2011;10(9):1720–7.View ArticlePubMedGoogle Scholar
  41. Baertsch MA, Leber MF, Bossow S, Singh M, Engeland CE, Albert J, et al. MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus. Cancer Gene Ther. 2014;21(9):373–80.View ArticlePubMedGoogle Scholar
  42. Liu Z, Jiang Z, Huang J, Huang S, Li Y, Yu S, et al. miR-7 inhibits glioblastoma growth by simultaneously interfering with the PI3K/ATK and Raf/MEK/ERK pathways. Int J Oncol. 2014;44(5):1571–80.PubMedGoogle Scholar
  43. Tamim S, Vo DT, Uren PJ, Qiao M, Bindewald E, Kasprzak WK, et al. Genomic analyses reveal broad impact of miR-137 on genes associated with malignant transformation and neuronal differentiation in glioblastoma cells. PLoS One. 2014;9(1):e85591.PubMed CentralView ArticlePubMedGoogle Scholar
  44. Wu DG, Wang YY, Fan LG, Luo H, Han B, Sun LH, et al. MicroRNA-7 regulates glioblastoma cell invasion via targeting focal adhesion kinase expression. Chin Med J (Engl). 2011;124(17):2616–21.Google Scholar
  45. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384–8.View ArticlePubMedGoogle Scholar
  46. Hansen TB, Kjems J, Damgaard CK. Circular RNA and miR-7 in cancer. Cancer Res. 2013;73(18):5609–12.View ArticlePubMedGoogle Scholar
  47. Zhang X, Hu S, Zhang X, Wang L, Zhang X, Yan B, et al. MicroRNA-7 arrests cell cycle in G1 phase by directly targeting CCNE1 in human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2014;443(3):1078–84.View ArticlePubMedGoogle Scholar
  48. Xu K, Chen Z, Qin C, Song X. miR-7 inhibits colorectal cancer cell proliferation and induces apoptosis by targeting XRCC2. Onco Targets Ther. 2014;7:325–32.PubMed CentralView ArticlePubMedGoogle Scholar
  49. Xie J, Chen M, Zhou J, Mo MS, Zhu LH, Liu YP, et al. miR-7 inhibits the invasion and metastasis of gastric cancer cells by suppressing epidermal growth factor receptor expression. Oncol Rep. 2014;31(4):1715–22.PubMedGoogle Scholar
  50. Zhou X, Hu Y, Dai L, Wang Y, Zhou J, Wang W, et al. MicroRNA-7 inhibits tumor metastasis and reverses epithelial-mesenchymal transition through AKT/ERK1/2 inactivation by targeting EGFR in epithelial ovarian cancer. PLoS One. 2014;9(5):e96718.PubMed CentralView ArticlePubMedGoogle Scholar
  51. Needhamsen M, White RB, Giles KM, Dunlop SA, Thomas MG. Regulation of Human PAX6 Expression by miR-7. Evol Bioinform Online. 2014;10:107–13.PubMed CentralView ArticlePubMedGoogle Scholar
  52. Salem CE, Markl ID, Bender CM, Gonzales FA, Jones PA, Liang G. PAX6 methylation and ectopic expression in human tumor cells. Int J Cancer. 2000;87(2):179–85.View ArticlePubMedGoogle Scholar
  53. Li Y, Li Y, Liu Y, Xie P, Li F, Li G. PAX6, a novel target of microRNA-7, promotes cellular proliferation and invasion in human colorectal cancer cells. Dig Dis Sci. 2014;59(3):598–606.View ArticlePubMedGoogle Scholar
  54. Zhang N, Li X, Wu CW, Dong Y, Cai M, Mok MT, et al. microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis. Oncogene. 2013;32(42):5078–88.View ArticlePubMedGoogle Scholar
  55. Fang Y, Xue JL, Shen Q, Chen J, Tian L. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology. 2012;55(6):1852–62.View ArticlePubMedGoogle Scholar
  56. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA. 2004;101(32):11755–60.PubMed CentralView ArticlePubMedGoogle Scholar
  57. Zhao X, Dou W, He L, Liang S, Tie J, Liu C, et al. MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. Oncogene. 2013;32(11):1363–72.View ArticlePubMedGoogle Scholar
  58. Cheng J, Guo S, Chen S, Mastriano SJ, Liu C, D’Alessio AC, et al. An extensive network of TET2-targeting MicroRNAs regulates malignant hematopoiesis. Cell Rep. 2013;5(2):471–81.View ArticlePubMedGoogle Scholar
  59. Veerla S, Lindgren D, Kvist A, Frigyesi A, Staaf J, Persson H, et al. MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer. 2009;124(9):2236–42.View ArticlePubMedGoogle Scholar
  60. Liu S, Zhang P, Chen Z, Liu M, Li X, Tang H. MicroRNA-7 downregulates XIAP expression to suppress cell growth and promote apoptosis in cervical cancer cells. FEBS Lett. 2013;587(14):2247–53.View ArticlePubMedGoogle Scholar
  61. Yu Z, Ni L, Chen D, Zhang Q, Su Z, Wang Y, et al. Identification of miR-7 as an oncogene in renal cell carcinoma. J Mol Histol. 2013;44(6):669–77.View ArticlePubMedGoogle Scholar
  62. Giles KM, Brown RA, Epis MR, Kalinowski FC, Leedman PJ. miRNA-7-5p inhibits melanoma cell migration and invasion. Biochem Biophys Res Commun. 2013;430(2):706–10.View ArticlePubMedGoogle Scholar
  63. Jung HM, Phillips BL, Patel RS, Cohen DM, Jakymiw A, Kong WW, et al. Keratinization-associated miR-7 and miR-21 regulate tumor suppressor reversion-inducing cysteine-rich protein with kazal motifs (RECK) in oral cancer. J Biol Chem. 2012;287(35):29261–72.PubMed CentralView ArticlePubMedGoogle Scholar
  64. Chakrabarti M, Khandkar M, Banik NL, Ray SK. Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells. Brain Res. 2012;1454:1–13.PubMed CentralView ArticlePubMedGoogle Scholar
  65. Ikeda Y, Tanji E, Makino N, Kawata S, Furukawa T. MicroRNAs associated with mitogen-activated protein kinase in human pancreatic cancer. Mol Cancer Res. 2012;10(2):259–69.View ArticlePubMedGoogle Scholar
  66. Balatti V, Maniero S, Ferracin M, Veronese A, Negrini M, Ferrocci G, et al. MicroRNAs dysregulation in human malignant pleural mesothelioma. J Thorac Oncol. 2011;6(5):844–51.View ArticlePubMedGoogle Scholar
  67. Saydam O, Senol O, Würdinger T, Mizrak A, Ozdener GB, Stemmer-Rachamimov AO, et al. miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways. Cancer Res. 2011;71(3):852–61.PubMed CentralView ArticlePubMedGoogle Scholar
  68. Jiang L, Liu X, Chen Z, Jin Y, Heidbreder CE, Kolokythas A, et al. MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochem J. 2010;432(1):199–205.PubMed CentralView ArticlePubMedGoogle Scholar
  69. Kitano M, Rahbari R, Patterson EE, Steinberg SM, Prasad NB, Wang Y, et al. Evaluation of candidate diagnostic microRNAs in thyroid fine-needle aspiration biopsy samples. Thyroid. 2012;22(3):285–91.PubMed CentralView ArticlePubMedGoogle Scholar
  70. Wang S, Xiang J, Li Z, Lu S, Hu J, Gao X, et al. A plasma microRNA panel for early detection of colorectal cancer. Int J Cancer. 2015;136(1):152–61.View ArticlePubMedGoogle Scholar
  71. Ahmed FE, Ahmed NC, Vos PW, Bonnerup C, Atkins JN, Casey M, et al. Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle. Cancer Genom Proteom. 2013;10(3):93–113.Google Scholar
  72. Duncavage E, Goodgame B, Sezhiyan A, Govindan R, Pfeifer J. Use of microRNA expression levels to predict outcomes in resected stage I non-small cell lung cancer. J Thorac Oncol. 2010;5(11):1755–63.View ArticlePubMedGoogle Scholar
  73. Tazawa H, Yano S, Yoshida R, Yamasaki Y, Sasaki T, Hashimoto Y, et al. Genetically engineered oncolytic adenovirus induces autophagic cell death through an E2F1-microRNA-7-epidermal growth factor receptor axis. Int J Cancer. 2012;131(12):2939–50.View ArticlePubMedGoogle Scholar
  74. Lee KM, Choi EJ, Kim IA. microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. Radiother Oncol. 2011;101(1):171–6.View ArticlePubMedGoogle Scholar

Copyright

© Zhao et al. 2015